DIAGENS-B Surges Over 9% in Late Trading Following Annual Tech Licensing Revenue Soaring 331.7%, Signaling Commercial Viability of Medical AI Model

Stock News05-13

DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400.

The company recently disclosed its 2025 performance. Annual total revenue reached RMB 164 million, a sharp increase of 133.7% year-on-year. Gross profit was RMB 118 million, surging 157% compared to the previous year.

Financial reports indicate that revenue from the company's technology licensing business skyrocketed to RMB 84.34 million from RMB 19.54 million in the same period last year, a massive increase of 331.7%. This segment accounted for half of the total revenue for the first time, becoming the largest income source. The gross profit margin for the technology licensing business is close to 87.3%, nearly reaching the theoretical ceiling for the model service industry.

The 2025 annual report serves as the most powerful demonstration of the company's capabilities to date. The 332% surge in technology licensing revenue validates the feasibility of the commercial closed-loop for its large model. A market share of 30.6% maintains its absolute leading position in a policy-driven, essential sector. Furthermore, the endorsement of its iMedImage® foundational model by leading institutions such as Tencent profoundly confirms its strategic value as a global AI medical infrastructure service provider.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181281095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 15:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181281095","market":"us","top_or_hot":-1,"title":"DIAGENS-B Surges Over 9% in Late Trading Following Annual Tech Licensing Revenue Soaring 331.7%, Signaling Commercial Viability of Medical AI Model","media":"Stock News","content":"<p>DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400.</p>\n<p>The company recently disclosed its 2025 performance. Annual total revenue reached RMB 164 million, a sharp increase of 133.7% year-on-year. Gross profit was RMB 118 million, surging 157% compared to the previous year.</p>\n<p>Financial reports indicate that revenue from the company's technology licensing business skyrocketed to RMB 84.34 million from RMB 19.54 million in the same period last year, a massive increase of 331.7%. This segment accounted for half of the total revenue for the first time, becoming the largest income source. The gross profit margin for the technology licensing business is close to 87.3%, nearly reaching the theoretical ceiling for the model service industry.</p>\n<p>The 2025 annual report serves as the most powerful demonstration of the company's capabilities to date. The 332% surge in technology licensing revenue validates the feasibility of the commercial closed-loop for its large model. A market share of 30.6% maintains its absolute leading position in a policy-driven, essential sector. Furthermore, the endorsement of its iMedImage® foundational model by leading institutions such as Tencent profoundly confirms its strategic value as a global AI medical infrastructure service provider.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DIAGENS-B Surges Over 9% in Late Trading Following Annual Tech Licensing Revenue Soaring 331.7%, Signaling Commercial Viability of Medical AI Model</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDIAGENS-B Surges Over 9% in Late Trading Following Annual Tech Licensing Revenue Soaring 331.7%, Signaling Commercial Viability of Medical AI Model\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 15:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400.</p>\n<p>The company recently disclosed its 2025 performance. Annual total revenue reached RMB 164 million, a sharp increase of 133.7% year-on-year. Gross profit was RMB 118 million, surging 157% compared to the previous year.</p>\n<p>Financial reports indicate that revenue from the company's technology licensing business skyrocketed to RMB 84.34 million from RMB 19.54 million in the same period last year, a massive increase of 331.7%. This segment accounted for half of the total revenue for the first time, becoming the largest income source. The gross profit margin for the technology licensing business is close to 87.3%, nearly reaching the theoretical ceiling for the model service industry.</p>\n<p>The 2025 annual report serves as the most powerful demonstration of the company's capabilities to date. The 332% surge in technology licensing revenue validates the feasibility of the commercial closed-loop for its large model. A market share of 30.6% maintains its absolute leading position in a policy-driven, essential sector. Furthermore, the endorsement of its iMedImage® foundational model by leading institutions such as Tencent profoundly confirms its strategic value as a global AI medical infrastructure service provider.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1181281095","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181281095","pubTimestamp":1778657300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400. The company recently disclosed its 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"150261":"医疗A","VXUS":"国际股票ETF-Vanguard","02526":"德适-B","BK4588":"碎股","BK1100":"医疗保健设备","BK4585":"ETF&股票定投概念"},"translate_title":"DIAGENS-B在年度技术许可收入飙升331.7%后尾盘飙升超过9%，表明医疗人工智能模型的商业可行性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"150261":1,"VXUS":1,"02526":1},"content_text":"DIAGENS-B (02526) surged more than 9% in late trading. As of the latest update, the stock rose 9.01% to HK$326.8, with a turnover of HK$40,489,400.\nThe company recently disclosed its 2025 performance. Annual total revenue reached RMB 164 million, a sharp increase of 133.7% year-on-year. Gross profit was RMB 118 million, surging 157% compared to the previous year.\nFinancial reports indicate that revenue from the company's technology licensing business skyrocketed to RMB 84.34 million from RMB 19.54 million in the same period last year, a massive increase of 331.7%. This segment accounted for half of the total revenue for the first time, becoming the largest income source. The gross profit margin for the technology licensing business is close to 87.3%, nearly reaching the theoretical ceiling for the model service industry.\nThe 2025 annual report serves as the most powerful demonstration of the company's capabilities to date. The 332% surge in technology licensing revenue validates the feasibility of the commercial closed-loop for its large model. A market share of 30.6% maintains its absolute leading position in a policy-driven, essential sector. Furthermore, the endorsement of its iMedImage® foundational model by leading institutions such as Tencent profoundly confirms its strategic value as a global AI medical infrastructure service provider.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181281095","isCrawlerRequest":true}